Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective-Reference-Cited by-同舟云学术

Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective

Published:2024-03 Issue: Volume:38 Page:100841
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Houda Ilias^ORCID,Dickhoff Chris,Uyl-de Groot Carin A.,Damhuis Ronald A.M.,Reguart Noemi,Provencio Mariano,Levy Antonin^ORCID,Dziadziuszko Rafal^ORCID,Pompili Cecilia,Di Maio Massimo,Thomas Michael,Brunelli Alessandro,Popat Sanjay,Senan Suresh,Bahce Idris^ORCID

Publisher

Elsevier BV

Reference50 articles.

1. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe;Houda;Lancet Reg Health Eur,2024

2. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

3. Perioperative pembrolizumab for early-stage non-small-cell lung cancer;Wakelee;N Engl J Med,2023

4. Perioperative durvalumab for resectable non–small-cell lung cancer;Heymach;New Engl J Med,2023

5. LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC;Cascone;Ann Oncol,2023

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A regret theory-based even swaps method with complex linguistic information and its application in early-stage lung cancer treatment selection;Information Sciences;2024-10

2. Nose-on-Chip Nanobiosensors for Early Detection of Lung Cancer Breath Biomarkers;ACS Sensors;2024-09-09

3. The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: outstanding contribution and entering a new phase;Japanese Journal of Clinical Oncology;2024-08-19

4. Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions;Journal of Clinical Medicine;2024-07-18

5. The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma;Current Cancer Drug Targets;2024-07-05